tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
INmune Bio reports Q2 EPS ($1.05), consensus (38c)
PremiumThe FlyINmune Bio reports Q2 EPS ($1.05), consensus (38c)
1M ago
INmune Bio Completes Phase I/II Trial for INKmune™
Premium
Company Announcements
INmune Bio Completes Phase I/II Trial for INKmune™
1M ago
INmune Bio options imply 16.2% move in share price post-earnings
Premium
The Fly
INmune Bio options imply 16.2% move in share price post-earnings
1M ago
Largest borrow rate increases among liquid names
PremiumThe FlyLargest borrow rate increases among liquid names
2M ago
INmune Bio announces video detailing findings from Phase 2 MINDFuL trial
Premium
The Fly
INmune Bio announces video detailing findings from Phase 2 MINDFuL trial
2M ago
Inmune Bio Reveals Promising XPro™ Trial Results
Premium
Company Announcements
Inmune Bio Reveals Promising XPro™ Trial Results
2M ago
INmune Bio price target lowered to $8 from $30 at Maxim
PremiumThe FlyINmune Bio price target lowered to $8 from $30 at Maxim
3M ago
INmune Bio downgraded to Underperform from Outperform at Scotiabank
Premium
The Fly
INmune Bio downgraded to Underperform from Outperform at Scotiabank
3M ago
INmune Bio downgraded to Neutral from Buy at BTIG
Premium
The Fly
INmune Bio downgraded to Neutral from Buy at BTIG
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100